Aura Biosciences, Inc. (NASDAQ:AURA) Insider Sells $98,808.00 in Stock

Aura Biosciences, Inc. (NASDAQ:AURA) insider Los Pinos Elisabet De sold 9,200 shares of the firm’s stock in a transaction that occurred on Tuesday, October 29th. The stock was sold at an average price of $10.74, for a total transaction of $98,808.00. Following the sale, the insider now owns 320,647 shares of the company’s stock, valued at $3,443,748.78. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Los Pinos Elisabet De also recently made the following trade(s):

• On Friday, October 18th, Los Pinos Elisabet De sold 24,992 shares of Aura Biosciences stock. The shares were sold at an average price of $12.04, for a total value of $300,903.68.

Aura Biosciences Trading Up 0.8 %

Shares of Aura Biosciences stock opened at $10.44 on Friday. Aura Biosciences, Inc. has a 1 year low of $5.99 and a 1 year high of $12.38. The company has a market cap of $517.89 million, a P/E ratio of -5.83 and a beta of 0.37. The stock has a 50-day moving average price of $9.16 and a 200 day moving average price of $8.27.

Aura Biosciences (NASDAQ:AURA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.04. On average, equities analysts forecast that Aura Biosciences, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on AURA shares. Lifesci Capital upgraded Aura Biosciences to a “strong-buy” rating in a report on Monday, September 9th. Evercore ISI raised Aura Biosciences to a “strong-buy” rating in a research note on Monday, September 16th. Scotiabank boosted their price objective on Aura Biosciences from $20.00 to $23.00 and gave the stock a “sector outperform” rating in a report on Friday, October 18th. Cowen reiterated a “buy” rating on shares of Aura Biosciences in a report on Friday, October 18th. Finally, HC Wainwright boosted their price target on shares of Aura Biosciences from $21.00 to $22.00 and gave the company a “buy” rating in a report on Friday, October 18th. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $23.00.

Institutional Investors Weigh In On Aura Biosciences

A number of institutional investors have recently modified their holdings of the stock. American Century Companies Inc. acquired a new position in shares of Aura Biosciences in the second quarter worth $119,000. American International Group Inc. increased its position in Aura Biosciences by 27.4% in the 1st quarter. American International Group Inc. now owns 17,579 shares of the company’s stock worth $138,000 after purchasing an additional 3,782 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Aura Biosciences during the 1st quarter worth about $144,000. SG Americas Securities LLC acquired a new stake in shares of Aura Biosciences during the 3rd quarter valued at about $169,000. Finally, Rhumbline Advisers increased its holdings in Aura Biosciences by 39.6% in the second quarter. Rhumbline Advisers now owns 63,483 shares of the company’s stock worth $480,000 after buying an additional 18,011 shares during the last quarter. Institutional investors and hedge funds own 96.75% of the company’s stock.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.